Zacks Investment Research lowered shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) from a buy rating to a hold rating in a research report report published on Wednesday.

According to Zacks, “Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing therapies for liver diseases and gallstones. Galmed Pharmaceuticals Ltd. is based in Tel Aviv, Israel. “

Other equities research analysts have also issued research reports about the stock. Seaport Global Securities reissued a buy rating and issued a $19.00 price target on shares of Galmed Pharmaceuticals in a report on Friday, October 6th. Maxim Group set a $14.00 price target on shares of Galmed Pharmaceuticals and gave the stock a buy rating in a report on Thursday, October 5th. HC Wainwright raised their price target on shares of Galmed Pharmaceuticals from $12.00 to $18.00 and gave the stock a buy rating in a report on Tuesday, August 8th. Finally, ValuEngine raised shares of Galmed Pharmaceuticals from a sell rating to a hold rating in a report on Saturday, June 17th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company has a consensus rating of Buy and a consensus price target of $14.75.

Galmed Pharmaceuticals (NASDAQ:GLMD) opened at 8.87 on Wednesday. The firm’s market cap is $108.38 million. Galmed Pharmaceuticals has a 12-month low of $2.78 and a 12-month high of $9.59. The company has a 50-day moving average of $8.51 and a 200 day moving average of $6.60.

Galmed Pharmaceuticals (NASDAQ:GLMD) last announced its quarterly earnings results on Monday, July 31st. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.11. The business had revenue of $0.27 million for the quarter, compared to analyst estimates of $0.29 million. Galmed Pharmaceuticals had a negative net margin of 1,443.98% and a negative return on equity of 141.13%. Equities analysts expect that Galmed Pharmaceuticals will post ($0.94) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Galmed Pharmaceuticals Ltd. (GLMD) Lowered to “Hold” at Zacks Investment Research” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://www.watchlistnews.com/galmed-pharmaceuticals-ltd-glmd-lowered-to-hold-at-zacks-investment-research/1631543.html.

An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. KCG Holdings Inc. purchased a new stake in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the first quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 20,473 shares of the biopharmaceutical company’s stock, valued at approximately $100,000. KCG Holdings Inc. owned 0.17% of Galmed Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 8.32% of the company’s stock.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.

Get a free copy of the Zacks research report on Galmed Pharmaceuticals (GLMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Galmed Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.